AUTHORS
Etienne Leveille, MD, Ojas Chahal2, Eden Bramson3, Mark E Robinson, PhD4, Leonardo de la Parra Soto5, Kate Johnson6, Johanna Scott, PhD7, Edmund Kapelczak8, Katsu Funai, PhD9, Hongbo Chi, PhD10, Janis L Abkowitz, MD11, Markus Müschen, MD-PhD12
AFFILIATIONS
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 Department of Molecular and Medical Pharmacology, Los Angeles, California, United States
8 Department of Molecular and Medical Pharmacology, Los Angeles, California, United States
9 Diabetes and Metabolism Research Center, Salt Lake City, Utah, United States
10 Department of Immunology, Memphis, Tennessee, United States
11 Division of Hematology, Seattle, Washington, United States
12 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
ABSTRACT
Background and significance: Phospholipid (PL) homeostasis is essential for membrane integrity and cell survival. Synthesis of PL can be driven by de novo synthesis of phosphatidylcholine (PC) and phosphatidylethanolamine (PE), the two most common membrane PLs, or alternative pathways such as lysosomal salvage of exogenous lipids or the mitochondrial phosphatidylserine (PS) decarboxylase (PSD) pathway. However, the contribution and importance of these different pathways is not established in B-cell malignancies.
Results: Using comparative analyses of gene dependency profiles across cancer subtypes from the Cancer Dependency Map, we uncovered that B-cell malignancies are uniquely dependent on multiple genes involved in de novo PL metabolism. This most notably included FLVCR1, which was recently characterized as a major choline and ethanolamine importer and thus a critical gatekeeper of de novo PL synthesis.
To evaluate the role of FLVCR1 and de novo PL synthesis in B-cell malignancies, we generated ex vivo murine models of B-cell acute lymphoblastic leukemia (B-ALL) with inducible deletion of FLVCR1. Gene deletion led to decreased competitive fitness, increased apoptosis, and abrogation of colony formation capacity in B-ALL cells. Similarly, deletion of FLVCR1 subverted competitive fitness in B-cell lymphoma cell lines, confirming a critical role of FLVCR1 across B-cell malignancies.
To determine how FLVCR1 loss rewires PL metabolism, we performed metabolite tracing experiments with deuterated choline, serine, and ethanolamine isotopes. These experiments showed that FLVCR1 loss severely compromises de novo synthesis of both PC and PE and led to a compensatory upregulation of serine-labeled PE from the PSD pathway. Conversely, deletion of PISD, which drives the PSD pathway, led to compensation from the FLVCR1-driven de novo pathway, confirming mutual compensation between these two PL synthesis pathways. However, this compensation is partial, as PISD deletion also compromised B-cell malignancies fitness.
In line with our tracing data, lipidomics of FLVCR1-KO cells showed significant shifts in PL composition, including a decrease in PC and a remodeling of the PE lipidome toward species containing polyunsaturated fatty acids (PUFAs), notably arachidonic acid. In line with those results, deletion of PISD decreased arachidonic acid-containing PE and led to a major increase of arachidonic acid-containing PS.
PUFA-containing PLs, especially PEs, are the key substrate of ferroptosis, a type of cell death driven by iron-dependent peroxidation of membrane PLs. The shift of FLVCR1 KO cells toward PUFA-PE converged with CRISPR screens we performed under the selective pressure of the ferroptosis inducer RSL3, in which FLVCR1 emerged as a top synthetic lethal hit. Accordingly, loss of FLVCR1 increased lipid peroxidation and sensitized cells to ferroptosis, placing FLVCR1 as critical for both B-cell malignancies maintenance and protection against ferroptosis.
To characterize the mechanisms by which FLVCR1 loss compromises cell fitness, we performed whole-genome CRISPR knockout screens in a B-cell lymphoma cell line with deletion of FLVCR1 or AAVS1 control and compared gene dependency profiles across the two conditions. This identified CHMP4B as a top FLVCR1-specific synthetic lethal hit. CHMP4B is a component of the ESCRT-III membrane repair complex, which has previously been implicated in protection against ferroptosis. These findings suggest that FLVCR1 loss leads to membrane defects requiring active membrane repair to mitigate cell death. In addition, PCYT1A, the rate-limiting enzyme of the choline arm of the de novo PL synthesis, emerged as another top synthetic lethal hit, suggesting that residual de novo PC metabolism is critical for FLVCR1-KO cells, likely to provide substrates for PS synthesis that can then be used to generate PE via the PSD pathway.
Conclusions: We show that B-cell malignancies are uniquely dependent on de novo PL synthesis via FLVCR1. Loss of de novo PL synthesis led to an increase in the PSD pathway, which remodels the lipidome toward highly oxidizable PLs that lead to increased vulnerability to ferroptosis. In addition, CRISPR screens showed that FLVCR1 loss increases dependence on membrane repair proteins and residual de novo PC synthesis. This unique metabolic vulnerability has the potential to be targeted therapeutically and combined with other agents such as ferroptosis inducers.
DISCLOSURES
Etienne Leveille, MD: No relevant conflicts of interest to declare.